FY2024 Earnings Estimate for EW Issued By William Blair

Edwards Lifesciences Co. (NYSE:EW) – William Blair issued their FY2024 earnings per share estimates for Edwards Lifesciences in a research report issued on Tuesday, October 29th. William Blair analyst M. Kaczor forecasts that the medical research company will post earnings of $2.58 per share for the year. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.61 per share. William Blair also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.56 EPS.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the company posted $0.59 EPS. The firm’s revenue was up 8.9% on a year-over-year basis.

Other research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Barclays dropped their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Deutsche Bank Aktiengesellschaft decreased their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, July 25th. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Finally, Truist Financial cut their price objective on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Sixteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Stock Performance

EW opened at $68.63 on Thursday. The company has a 50 day simple moving average of $68.07 and a two-hundred day simple moving average of $77.92. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The firm has a market cap of $41.36 billion, a P/E ratio of 29.58, a PEG ratio of 3.00 and a beta of 1.13. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock valued at $1,099,238 in the last ninety days. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of the business. Concurrent Investment Advisors LLC increased its position in shares of Edwards Lifesciences by 3.4% during the third quarter. Concurrent Investment Advisors LLC now owns 19,187 shares of the medical research company’s stock worth $1,266,000 after acquiring an additional 636 shares during the period. Canal Insurance CO purchased a new position in Edwards Lifesciences during the 3rd quarter worth $660,000. Radnor Capital Management LLC raised its position in Edwards Lifesciences by 358.8% during the 3rd quarter. Radnor Capital Management LLC now owns 23,784 shares of the medical research company’s stock valued at $1,570,000 after purchasing an additional 18,600 shares in the last quarter. 1834 Investment Advisors Co. lifted its holdings in shares of Edwards Lifesciences by 8.4% in the 3rd quarter. 1834 Investment Advisors Co. now owns 9,218 shares of the medical research company’s stock worth $608,000 after buying an additional 715 shares during the period. Finally, Hixon Zuercher LLC grew its position in shares of Edwards Lifesciences by 1.1% during the 3rd quarter. Hixon Zuercher LLC now owns 27,617 shares of the medical research company’s stock worth $1,822,000 after buying an additional 312 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.